BD’s Post

Clinical Lab Products has featured this first-of-its-kind HPV self-collection screening pilot program aimed at improving cervical cancer screening in underserved communities. This groundbreaking study, conducted at Su Clinica in collaboration with researchers at The University of Texas MD Anderson Cancer Center, utilizes the BD Onclarity™ HPV Assay, one of only two FDA-approved HPV assays for self-collection in a healthcare setting in the United States: https://lnkd.in/eddyNQsX #HealthAccess #CervicalCancerScreening #BDOnclarity

𝐀 𝐧𝐞𝐰 𝐦𝐚𝐜𝐡𝐢𝐧𝐞 𝐥𝐞𝐚𝐫𝐧𝐢𝐧𝐠-𝐩𝐨𝐰𝐞𝐫𝐞𝐝 𝐛𝐥𝐨𝐨𝐝 𝐭𝐞𝐬𝐭 𝐜𝐚𝐧 𝐝𝐞𝐭𝐞𝐜𝐭 𝐦𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐭𝐲𝐩𝐞𝐬 𝐨𝐟 𝐜𝐚𝐧𝐜𝐞𝐫 𝐢𝐧 𝐭𝐡𝐞𝐢𝐫 𝐞𝐚𝐫𝐥𝐢𝐞𝐬𝐭 𝐬𝐭𝐚𝐠𝐞𝐬.   Researchers at Oxford University have developed TriOx, a machine learning-powered blood test that detects multiple cancers at their earliest stages!   Key Highlights:   1️⃣ TriOx analyzes DNA in the blood to identify subtle cancer markers—fast, sensitive, and minimally invasive.   2️⃣ Proven effective across 6 types of cancer, including colorectal, pancreatic, and breast cancers.   3️⃣ A potential game-changer for early detection, offering hope for improved outcomes and cost-efficient care.   Could this be the future of cancer screening? You can read the full article, here ⬇️     https://lnkd.in/edcSvj8S

Great to see Clinical Lab Products feature this first-of-its-kind HPV self-collection screening pilot program aimed at improving cervical cancer screening in underserved communities. Launched in Texas at Su Clinica, together with researchers at The University of Texas MD Anderson Cancer Center, the program uses the BD Onclarity™ HPV Assay, one of only two FDA-approved HPV assays for self-collection in a healthcare setting in the United States. #HealthEquity #CervicalCancerScreening #BDOnclarity #BDemployee https://bit.ly/4gbeesE

Cervical cancer is preventable, and early detection saves lives. The FDA recently approved two new cervical cancer screening tests that enable self-collection in clinical settings, with hopes of expanding access for at-home use in the future. These innovative methods make screening more convenient and less invasive. Deanna Kepka, MPH, PhD, walks us through the latest developments in cervical cancer screening: https://bit.ly/3BYjS2v

It's Cervical Cancer Awareness Month!!! Most cervical cancers are caused by the Human Papilloma Virus (HPV). Getting the HPV vaccine can significantly reduce the risk of developing cervical cancer, early detection saves too. Book that appointment today!!! #CervicalCancerAwarenessMonth #CervicalCancer #GeneLabBioscience

Great to see Clinical Lab Products feature this first-of-its-kind HPV self-collection screening pilot program aimed at improving cervical cancer screening in underserved communities. Launched in Texas at Su Clinica, together with researchers at The University of Texas MD Anderson Cancer Center, the program uses the BD Onclarity™ HPV Assay, one of only two FDA-approved HPV assays for self-collection in a healthcare setting in the United States. #HealthEquity #CervicalCancerScreening #BDOnclarity #BDemployee https://bit.ly/3ZxWSPx

Colorectal cancer is the second leading cause of cancer-related death in the United States. Yet nearly one in three adults ages 45-74 is not up to date with current guideline recommendations for colorectal cancer screening.    To close this gap, continued advancement and acceleration of screening test innovation is needed. The introduction of the Cologuard® test a decade ago illustrates what a patient-centric approach can achieve, and we must apply this attitude towards new screening tests to make a real impact on cancer outcomes. https://lnkd.in/gGnCJGKJ

New publication in cervical cancer.. Developing new algorithm to classify cervical cancer cells. https://lnkd.in/e7dTkkqr Cervical cancer is a significant concern for women, necessitating early detection and precise treatment. Conventional cytological methods often fall short in early diagnosis. The proposed innovative Heap Optimizer-based Self-Systematized Neural Fuzzy (HO-SsNF) method offers a viable solution with 99.6% accuracy in classifying cervical cancer cells. The resulting insights provide a foundation for advancing cancer prevention methods

Great to see Clinical Lab Products feature this first-of-its-kind HPV self-collection screening pilot program aimed at improving cervical cancer screening in underserved communities. Launched in Texas at Su Clinica, together with researchers at The University of Texas MD Anderson Cancer Center, the program uses the BD Onclarity™ HPV Assay, one of only two FDA-approved HPV assays for self-collection in a healthcare setting in the United States. #HealthEquity #CervicalCancerScreening #BDOnclarity #BDemployee https://bit.ly/49zXgSf

Do you want to see how you can exploit our solutions to explore unanswered questions in EV field? In a recent study, Chao Li, Agustin E., Roman Koning, Mona Shahsavari, and Peter ten Dijke investigated the role of TGF-β in cancer progression through extracellular vesicles. In the process, they preferred our TFF-EVs and EV Spinner as part of their EV isolation protocol in response to the high recovery and purity requirement of quantitative analyses. Through a multi-step characterization process, the researchers successfully demonstrated that TGF-β stimulation not only suppresses EV release, but also alters EV morphology and protein cargo in breast cancer cells. Their findings suggest that TGF-β inhibits CD8-positive T-cell mediated killing of breast cancer cells, thereby deteriorating the immune response. If you are interested in further reading: https://lnkd.in/daGMWBBE #extracellularvesicles #exosomes #EVisolation #cancer